patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_400565 | REC_0008601 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 17.1 | 73 | female | 1 | 16 | 5 | 5 | sotorasib 960 mg daily | 10.3 | false | MSS | 2026-03-15T05:35:58.972806+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_337641 | REC_0008602 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 26 | 15.1 | 85 | female | 2 | 7 | 4.8 | 0 | osimertinib 80 mg daily | 37.3 | false | MSS | 2026-03-15T05:35:58.973036+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_410656 | REC_0008603 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 12.6 | 62 | male | 0 | 25 | 5.1 | 7 | osimertinib 80 mg daily | 13.2 | true | MSI-H | 2026-03-15T05:35:58.973275+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_478789 | REC_0008604 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 21.2 | 67 | male | 0 | 10 | 7 | 7 | entrectinib 600 mg daily | 9.3 | true | MSI-H | 2026-03-15T05:35:58.973510+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_868682 | REC_0008605 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 30 | 8.7 | 74 | female | 2 | 16 | 3.4 | 5 | pembrolizumab 200 mg q3w | 10.3 | false | MSS | 2026-03-15T05:35:58.973738+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_390492 | REC_0008606 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 19.5 | 69 | male | 1 | 17 | 6 | 3 | sotorasib 960 mg daily | 14.5 | true | MSS | 2026-03-15T05:35:58.973971+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_796827 | REC_0008607 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 6 | 54 | male | 0 | 28 | 3.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.6 | true | MSS | 2026-03-15T05:35:58.974246+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_368872 | REC_0008608 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 7.1 | 66 | female | 0 | 11 | 3.2 | 1 | osimertinib 80 mg daily | 27.3 | true | MSS | 2026-03-15T05:35:58.974479+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_943569 | REC_0008609 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 11.2 | 75 | female | 2 | 7 | 7.4 | 1 | alectinib 600 mg BID | 15.6 | true | MSI-H | 2026-03-15T05:35:58.974710+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_679796 | REC_0008610 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 13.9 | 69 | female | 1 | 10 | 5.2 | 5 | sotorasib 960 mg daily | 5.6 | false | MSS | 2026-03-15T05:35:58.974945+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_605375 | REC_0008611 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 13.4 | 79 | male | 1 | 23 | 6.8 | 6 | alectinib 600 mg BID | 12.9 | true | MSI-H | 2026-03-15T05:35:58.975179+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_806634 | REC_0008612 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 11.7 | 84 | female | 2 | 17 | 6.3 | 5 | entrectinib 600 mg daily | 14.2 | false | MSI-H | 2026-03-15T05:35:58.975411+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_801681 | REC_0008613 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 15.4 | 69 | female | 1 | 18 | 7.5 | 3 | entrectinib 600 mg daily | 9.6 | true | MSS | 2026-03-15T05:35:58.975643+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_820430 | REC_0008614 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 3.6 | 73 | female | 3 | 12 | 4.9 | 4 | pembrolizumab 200 mg q3w | 9.4 | false | MSS | 2026-03-15T05:35:58.975874+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_286620 | REC_0008615 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 14.6 | 75 | female | 1 | 9 | 4.5 | 5 | alectinib 600 mg BID | 11 | false | MSI-H | 2026-03-15T05:35:58.976195+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_604805 | REC_0008616 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 7 | 66 | male | 0 | 24 | 4 | 7 | alectinib 600 mg BID | 12.8 | false | MSS | 2026-03-15T05:35:58.976433+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_304015 | REC_0008617 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 8.3 | 65 | male | 1 | 12 | 5.7 | 2 | osimertinib 80 mg daily | 16.8 | true | MSS | 2026-03-15T05:35:58.976664+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_557833 | REC_0008618 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 13.6 | 79 | female | 1 | 14 | 3.8 | 9 | osimertinib 80 mg daily | 7.6 | true | MSS | 2026-03-15T05:35:58.976899+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_795695 | REC_0008619 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 3.9 | 74 | female | 2 | 24 | 6.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 8.2 | false | MSS | 2026-03-15T05:35:58.977129+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941525 | REC_0008620 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 8 | 67 | male | 0 | 13 | 5.5 | 4 | osimertinib 80 mg daily | 13.6 | true | MSS | 2026-03-15T05:35:58.977404+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_148670 | REC_0008621 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 11 | 64 | female | 1 | 17 | 6.9 | 2 | sotorasib 960 mg daily | 8.2 | true | MSI-H | 2026-03-15T05:35:58.977643+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_276009 | REC_0008622 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 12.3 | 73 | female | 1 | 22 | 5.3 | 2 | osimertinib 80 mg daily | 12.5 | true | MSS | 2026-03-15T05:35:58.977874+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_623220 | REC_0008623 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 33 | 3.5 | 63 | female | 0 | 50 | 4.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.6 | false | MSS | 2026-03-15T05:35:58.978106+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_502006 | REC_0008624 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 12.8 | 64 | female | 0 | 17 | 4.3 | 7 | osimertinib 80 mg daily | 13.4 | true | MSI-H | 2026-03-15T05:35:58.978339+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_574633 | REC_0008625 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 16.7 | 65 | female | 1 | 18 | 6 | 5 | osimertinib 80 mg daily | 9.7 | true | MSS | 2026-03-15T05:35:58.978575+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_345816 | REC_0008626 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 4.9 | 61 | female | 0 | 37 | 4.9 | 8 | pembrolizumab 200 mg q3w | 7.5 | false | MSS | 2026-03-15T05:35:58.978803+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_510699 | REC_0008627 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 6.1 | 58 | male | 0 | 46 | 6.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 16 | true | MSS | 2026-03-15T05:35:58.979035+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_919147 | REC_0008628 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 3.9 | 63 | female | 0 | 24 | 6.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 5.5 | true | MSS | 2026-03-15T05:35:58.979268+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_408162 | REC_0008629 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 30 | 4.2 | 58 | female | 1 | 67 | 6.3 | 4 | pembrolizumab 200 mg q3w | 8 | true | MSS | 2026-03-15T05:35:58.979500+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_383912 | REC_0008630 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 11 | 12.6 | 60 | male | 1 | 14 | 5.6 | 5 | osimertinib 80 mg daily | 11 | false | MSI-H | 2026-03-15T05:35:58.979735+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_694129 | REC_0008631 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 38 | 11 | 67 | female | 0 | 14 | 5.1 | 2 | entrectinib 600 mg daily | 18.7 | true | MSS | 2026-03-15T05:35:58.979966+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_882768 | REC_0008632 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 4.4 | 83 | female | 0 | 7 | 5.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.8 | true | MSS | 2026-03-15T05:35:58.980217+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_776169 | REC_0008633 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 13.8 | 63 | female | 0 | 10 | 6.4 | 6 | osimertinib 80 mg daily | 8.4 | false | MSS | 2026-03-15T05:35:58.980499+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_907637 | REC_0008634 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 8.3 | 66 | female | 0 | 63 | 7.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.1 | true | MSS | 2026-03-15T05:35:58.980730+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_110401 | REC_0008635 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 4.3 | 75 | female | 2 | 92 | 5.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.5 | false | MSS | 2026-03-15T05:35:58.980959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_638426 | REC_0008636 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 35 | 10.8 | 63 | male | 0 | 14 | 6.6 | 5 | pembrolizumab 200 mg q3w | 9.1 | true | MSS | 2026-03-15T05:35:58.981196+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_942131 | REC_0008637 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 14 | 61 | female | 1 | 19 | 7.8 | 8 | entrectinib 600 mg daily | 15.4 | true | MSI-H | 2026-03-15T05:35:58.981430+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_160039 | REC_0008638 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 14 | 73 | female | 2 | 14 | 6.5 | 2 | osimertinib 80 mg daily | 30.8 | true | MSI-H | 2026-03-15T05:35:58.981664+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_542979 | REC_0008639 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 2.2 | 67 | male | 1 | 76 | 6.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 18.6 | false | MSS | 2026-03-15T05:35:58.981895+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_274735 | REC_0008640 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 10 | 71 | female | 2 | 20 | 7.3 | 5 | osimertinib 80 mg daily | 14.2 | false | MSI-H | 2026-03-15T05:35:58.982126+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_490081 | REC_0008641 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 16.6 | 65 | male | 1 | 6 | 4.7 | 2 | sotorasib 960 mg daily | 19.4 | false | MSI-H | 2026-03-15T05:35:58.982361+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_451274 | REC_0008642 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 15.4 | 68 | female | 1 | 8 | 5.8 | 6 | alectinib 600 mg BID | 11.9 | false | MSS | 2026-03-15T05:35:58.982593+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988909 | REC_0008643 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 9.3 | 75 | female | 1 | 24 | 5.9 | 2 | osimertinib 80 mg daily | 14.3 | false | MSS | 2026-03-15T05:35:58.982821+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_124187 | REC_0008644 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 8.2 | 63 | male | 0 | 24 | 6.1 | 7 | entrectinib 600 mg daily | 7.8 | false | MSS | 2026-03-15T05:35:58.983051+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_324318 | REC_0008645 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 18 | 15.6 | 67 | female | 0 | 8 | 3 | 6 | pembrolizumab 200 mg q3w | 11.7 | true | MSS | 2026-03-15T05:35:58.983283+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_901992 | REC_0008646 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 9 | 70 | male | 2 | 27 | 4.7 | 1 | osimertinib 80 mg daily | 16.4 | true | MSS | 2026-03-15T05:35:58.983555+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144104 | REC_0008647 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 3.1 | 84 | female | 1 | 8 | 3.3 | 8 | pembrolizumab 200 mg q3w | 15 | false | MSS | 2026-03-15T05:35:58.983785+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_507398 | REC_0008648 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 10.2 | 51 | male | 0 | 16 | 5.9 | 1 | osimertinib 80 mg daily | 36.5 | true | MSS | 2026-03-15T05:35:58.984018+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_804008 | REC_0008649 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 13.6 | 64 | male | 1 | 19 | 6.8 | 2 | alectinib 600 mg BID | 12.2 | true | MSI-H | 2026-03-15T05:35:58.984302+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_770543 | REC_0008650 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 22 | 13.7 | 64 | female | 0 | 15 | 6.3 | 0 | entrectinib 600 mg daily | 34.2 | true | MSI-H | 2026-03-15T05:35:58.984552+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_802467 | REC_0008651 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.1 | 73 | female | 2 | 34 | 3.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.6 | false | MSS | 2026-03-15T05:35:58.984782+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_189198 | REC_0008652 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 3.9 | 56 | female | 1 | 50 | 6.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.9 | false | MSS | 2026-03-15T05:35:58.985013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_346501 | REC_0008653 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 11.7 | 55 | female | 1 | 13 | 6.4 | 8 | sotorasib 960 mg daily | 12 | false | MSS | 2026-03-15T05:35:58.985252+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_448714 | REC_0008654 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 6.1 | 61 | female | 0 | 14 | 5.5 | 6 | sotorasib 960 mg daily | 9.9 | false | MSS | 2026-03-15T05:35:58.985483+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_555331 | REC_0008655 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 10 | 62 | male | 0 | 24 | 7.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 13.9 | true | MSI-H | 2026-03-15T05:35:58.985720+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_352553 | REC_0008656 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 14.6 | 70 | male | 1 | 3 | 5.9 | 4 | sotorasib 960 mg daily | 15.6 | true | MSI-H | 2026-03-15T05:35:58.985955+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_944528 | REC_0008657 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 14.3 | 68 | male | 1 | 12 | 4.9 | 5 | entrectinib 600 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:58.986194+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_151811 | REC_0008658 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 12.3 | 71 | female | 2 | 22 | 4.1 | 1 | sotorasib 960 mg daily | 6.2 | true | MSS | 2026-03-15T05:35:58.986425+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_448001 | REC_0008659 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 23 | 13.5 | 74 | female | 2 | 15 | 7.1 | 0 | sotorasib 960 mg daily | 46.7 | true | MSS | 2026-03-15T05:35:58.986702+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_986387 | REC_0008660 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 12.3 | 49 | male | 0 | 10 | 5.4 | 6 | sotorasib 960 mg daily | 14.4 | false | MSI-H | 2026-03-15T05:35:58.986939+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_903718 | REC_0008661 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 13.7 | 65 | female | 0 | 10 | 4.2 | 5 | osimertinib 80 mg daily | 12.6 | true | MSS | 2026-03-15T05:35:58.987176+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_234802 | REC_0008662 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 12.3 | 63 | female | 0 | 8 | 6.3 | 7 | osimertinib 80 mg daily | 6.2 | false | MSI-H | 2026-03-15T05:35:58.987412+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381654 | REC_0008663 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 19.2 | 64 | female | 1 | 16 | 7.4 | 2 | osimertinib 80 mg daily | 13.9 | false | MSI-H | 2026-03-15T05:35:58.987647+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855532 | REC_0008664 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 12.8 | 84 | female | 2 | 18 | 3.2 | 8 | osimertinib 80 mg daily | 13.6 | false | MSI-H | 2026-03-15T05:35:58.987883+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_202391 | REC_0008665 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 5.6 | 60 | female | 1 | 64 | 8.1 | 7 | carboplatin + paclitaxel + pembrolizumab | 8.9 | true | MSS | 2026-03-15T05:35:58.988140+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_916293 | REC_0008666 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 10.2 | 67 | female | 0 | 17 | 7 | 5 | osimertinib 80 mg daily | 13.6 | false | MSS | 2026-03-15T05:35:58.988377+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_570871 | REC_0008667 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 12 | 73 | female | 2 | 21 | 4.4 | 6 | entrectinib 600 mg daily | 6.2 | false | MSS | 2026-03-15T05:35:58.988609+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_707540 | REC_0008668 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 10.1 | 65 | male | 1 | 23 | 5.3 | 5 | alectinib 600 mg BID | 14.5 | true | MSI-H | 2026-03-15T05:35:58.988845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_956265 | REC_0008669 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 31 | 7.1 | 81 | female | 1 | 66 | 4.9 | 6 | pembrolizumab 200 mg q3w | 10.2 | true | MSS | 2026-03-15T05:35:58.989074+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_259357 | REC_0008670 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 14.2 | 58 | female | 0 | 17 | 6.1 | 6 | osimertinib 80 mg daily | 16.3 | false | MSI-H | 2026-03-15T05:35:58.989311+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_702169 | REC_0008671 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 9.6 | 56 | male | 0 | 17 | 6.6 | 6 | entrectinib 600 mg daily | 10.4 | false | MSS | 2026-03-15T05:35:58.989543+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_257079 | REC_0008672 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 17.9 | 75 | male | 0 | 26 | 4.9 | 6 | osimertinib 80 mg daily | 9.9 | false | MSS | 2026-03-15T05:35:58.989826+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_822290 | REC_0008673 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 20 | 4.6 | 72 | female | 2 | 16 | 5.4 | 5 | pembrolizumab 200 mg q3w | 10.1 | false | MSS | 2026-03-15T05:35:58.990057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132766 | REC_0008674 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 6.8 | 65 | female | 0 | 68 | 6.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 23.6 | true | MSS | 2026-03-15T05:35:58.990290+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_355738 | REC_0008675 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 17 | 67 | female | 0 | 9 | 7.1 | 6 | entrectinib 600 mg daily | 11.2 | true | MSI-H | 2026-03-15T05:35:58.990522+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_907091 | REC_0008676 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 11.3 | 68 | female | 0 | 16 | 4.7 | 2 | alectinib 600 mg BID | 17.2 | true | MSS | 2026-03-15T05:35:58.990757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_320229 | REC_0008677 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 30 | 8.6 | 74 | female | 2 | 10 | 4.2 | 0 | osimertinib 80 mg daily | 60.2 | true | MSS | 2026-03-15T05:35:58.990987+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_438528 | REC_0008678 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 18 | 15.1 | 74 | female | 2 | 23 | 8.3 | 7 | pembrolizumab 200 mg q3w | 7.8 | true | MSI-H | 2026-03-15T05:35:58.991220+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_321983 | REC_0008679 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 13.5 | 79 | female | 1 | 12 | 4.5 | 8 | entrectinib 600 mg daily | 10.2 | true | MSI-H | 2026-03-15T05:35:58.991454+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_394163 | REC_0008680 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 9.9 | 51 | female | 0 | 11 | 7.2 | 2 | sotorasib 960 mg daily | 20.6 | false | MSS | 2026-03-15T05:35:58.991688+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_987083 | REC_0008681 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 8 | 68 | female | 1 | 10 | 7.4 | 5 | pembrolizumab 200 mg q3w | 12.4 | true | MSS | 2026-03-15T05:35:58.991917+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_845535 | REC_0008682 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 15.5 | 86 | female | 1 | 25 | 6.3 | 5 | sotorasib 960 mg daily | 10.2 | false | MSI-H | 2026-03-15T05:35:58.992180+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_703135 | REC_0008683 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 19 | 7.4 | 74 | female | 2 | 9 | 4.8 | 5 | pembrolizumab 200 mg q3w | 8.1 | false | MSS | 2026-03-15T05:35:58.992412+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_989188 | REC_0008684 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 7.6 | 64 | male | 1 | 20 | 5.8 | 4 | sotorasib 960 mg daily | 13.8 | false | MSS | 2026-03-15T05:35:58.992644+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_177204 | REC_0008685 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 8.2 | 81 | male | 2 | 12 | 7.2 | 1 | entrectinib 600 mg daily | 20 | true | MSS | 2026-03-15T05:35:58.992928+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_892616 | REC_0008686 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 10.4 | 85 | female | 2 | 24 | 5.8 | 8 | osimertinib 80 mg daily | 12 | true | MSI-H | 2026-03-15T05:35:58.993171+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_312596 | REC_0008687 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 16 | 12.7 | 80 | female | 1 | 17 | 4.8 | 4 | osimertinib 80 mg daily | 8.4 | true | MSS | 2026-03-15T05:35:58.993410+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_396453 | REC_0008688 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 10.9 | 67 | female | 0 | 19 | 5.1 | 1 | entrectinib 600 mg daily | 23.1 | false | MSI-H | 2026-03-15T05:35:58.993642+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535683 | REC_0008689 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 9.3 | 52 | male | 0 | 17 | 6.6 | 2 | alectinib 600 mg BID | 8.4 | true | MSS | 2026-03-15T05:35:58.993874+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_861650 | REC_0008690 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 33 | 15 | 87 | female | 1 | 9 | 6.1 | 2 | pembrolizumab 200 mg q3w | 22.2 | false | MSS | 2026-03-15T05:35:58.994105+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_211012 | REC_0008691 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 9.4 | 54 | female | 0 | 13 | 6.1 | 1 | sotorasib 960 mg daily | 21.3 | true | MSS | 2026-03-15T05:35:58.994339+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_557283 | REC_0008692 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 7.2 | 68 | female | 1 | 51 | 6.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 30.8 | false | MSS | 2026-03-15T05:35:58.994571+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_765345 | REC_0008693 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 18.4 | 78 | male | 1 | 13 | 6.8 | 1 | sotorasib 960 mg daily | 13.7 | false | MSI-H | 2026-03-15T05:35:58.994808+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_462317 | REC_0008694 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 29 | 8 | 54 | male | 0 | 12 | 5.2 | 4 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:35:58.995041+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_873934 | REC_0008695 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 23.7 | 66 | male | 1 | 32 | 4.5 | 2 | osimertinib 80 mg daily | 6 | false | MSS | 2026-03-15T05:35:58.995277+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_176546 | REC_0008696 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 6.2 | 74 | female | 1 | 16 | 5.3 | 4 | alectinib 600 mg BID | 16.4 | false | MSS | 2026-03-15T05:35:58.995508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_702551 | REC_0008697 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 20 | 7.8 | 68 | female | 0 | 67 | 4.6 | 0 | carboplatin + paclitaxel + pembrolizumab | 22.4 | true | MSS | 2026-03-15T05:35:58.995735+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_533220 | REC_0008698 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 7.8 | 73 | male | 1 | 61 | 5.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 19.3 | false | MSS | 2026-03-15T05:35:58.996009+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_174182 | REC_0008699 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 7.6 | 73 | female | 1 | 51 | 6.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 13.5 | true | MSS | 2026-03-15T05:35:58.996350+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_540758 | REC_0008700 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 12.2 | 56 | male | 1 | 12 | 4.1 | 9 | pembrolizumab 200 mg q3w | 13.7 | false | MSS | 2026-03-15T05:35:58.996609+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.